GC Genome, a subsidiary of GC Biopharma, successfully raised approximately 2.5 trillion won in its general subscription for listing on the KOSDAQ market. Established in 2013, GC Genome is a company specializing in liquid biopsy and clinical genomics.
GC Genome stated on the 30th that it recorded a competition ratio of 484.1 to 1 in the two-day subscription conducted for general investors starting on the 29th. The total subscription deposit amounted to 2.5415 trillion won.
GC Genome plans to issue 4 million shares through this public offering. The total offering amount is 42 billion won, and the market capitalization after listing is 248.3 billion won.
Earlier, a total of 1,692 institutions participated in the demand forecast for institutional investors, recording a competition ratio of 547.47 to 1. The final offering price was confirmed at the upper end of the desired range, 10,500 won. About 95.87% of the participating institutions proposed prices above the upper band.
GC Genome, established in 2013 as a subsidiary of GC Biopharma, is a company specializing in liquid biopsy and clinical genomic analysis. Currently, it offers over 300 types of genetic testing services to more than 900 hospitals and clinics, including health check-ups, prenatal and newborn, precision cancer diagnostics, and precision diagnostics for genetic rare diseases.
GC Genome is scheduled to be listed on the KOSDAQ market on the 11th of next month after payment on the 4th. Samsung Securities is acting as the lead underwriter. Samsung Securities provided a put-back option to public stock investors, allowing them to buy back at 90% of the offering price for three months.